These data support a model in which TMZ-resistant GBM cells have rewired their splicing regulatory machinery over time, exhibiting deregulation of SR protein phosphorylation and CLK2 function, and show that pharmacological inhibition of CLK2 may selectively target these alterations, leading to decreased cell proliferation and increased cell death. This evidence concerns the gene CLK2 and glioblastoma.